Lymphomas chronic lymphocytic leukemia/small

Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma Mature (peripheral) B-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma... 

B cell neoplasms based on morphology, immunophenotype, and genotype often, but not always, correspond to stages of B cell development. However, some B cell lymphomas either do not clearly correspond to a specific developmental stage (i.e., appear to be of variable origin such as chronic lymphocytic leukemia/small lymphocytic lymphoma) or do not appear to be related to any known stage of normal development (i.e., hairy cell leukemia) (H10). 

CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic lymphoma MCL, mantle cell lymphoma FL, follicular lymphoma MZL/MALT, marginal zone lymphoma/mucosa-associated lymphoid tisuse lymphoma SMZL, splenic marginal zone lymphoma HCL, hairy cell leukemia DLCL, diffuse large-cell lymphoma PCM, plasma cell myeloma BCL-1, cyclin D1 FDC MW, Follicular dendritic cell meshworks CK, cytokeratin LELs, lymphoepitheilal lesions. 

D26. Dunphy, C. H., Wheaton, S. E., and Perkins, S. L., CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic tranformations of mantle cell lymphoma. Mod. Pathol. 10, 818-822 (1997). 

K8. Kilo, M. N., and Dorfman, D. M., The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am. J. Clin. Pathol. 105, 451—457 (1996). 

K30. Kroft, S. H., Dawson, D. B., and McKenna, R. W., Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. Am. J. Clin. Pathol. 115, 385-395 (2001). 

CD25 functions as a low-affinity interleukin-2 receptor and may be found on a number of cell types including activated T cells. This antigen is characteristically expressed on hairy cell leukemia, mast cell lesions, and certain T-cell malignancies but may be seen at low levels in certain B-cell lymphomas, particularly small cell lymphocytic lymphoma/chronic lymphocytic leukemia. Targeted therapy is available for this antigen (Ontak). 

B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA... 

INTERPHASE FISH Several recurrent genetic abnormalities identified in small cell lymphocytic lymphoma/chronic lymphocytic leukemia have had a direct relationship to disease progression. These abnormalities are ... 

Hairy cell leukemia chronic lymphocytic leukemia small cell non-Hodgkin s lymphoma... 

Shao H, Xi L, Raffeld M, Feldman AL, Kettoling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES. Clonally related histiocytic/dendtitic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma a study of seven cases. Mod Pathol. 2011 24 1421-32. 

Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E., and Greco, RA., Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma a phase II trial of the Minnie Pearl Gancer Research Network, /. Clin. Oncol., 21,1746-2751, 2003. 

Another small-molecule pan-Bcl-2 inhibitor that mimicks BH3-only proteins, GX15-070 (developed by GeminX, Montreal, Canada) (Fig. 3k), was shown to be a potent apoptosis inducer in breast cancer, chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma cell lines (76-79). 

Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma implications for clinical trials in this patient population. Cancer 2002 94(7) 2033-9. 

ANLL, acute nonleukocytic leukemia ALL, acute lymphocytic leukemia BM, bone marrow CIcr, creatinine clearance CLL, chronic lymphocytic leukemia CML, chronic myelogenous leukemia DNA, deoxyribonucleic acid HD, Hodgkin s disease HSV, herpes simplex virus IT, intrathecal MDS, myelodysplastic syndrome NHL, non-Hodgkin s lymphoma NSCLC, non-small-cell lung cancer PCP, Pneumocystis carinii pneumonia RNA, ribonucleic acid WBC, white blood cells. 

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)... 

NHL non-Hodgkin s lymphoma CLL chronic lymphocytic leukemia AML acute myelogenous leukemia CRC colorectal cancer NSCLC non-small cell lung cancer EGFR epidermal growth factor receptor VEGF vascular endothehal growth factor. 

Pharmacyclics acquired Celera s small molecule Btk inhibitor program in April 2006 subsequently, PCI-32765 (ibrutinib) was chosen for further preclinical and clinical developments. Ibrutinib (trade name Imbruvica), currently jointly developed and marketed by Pharmacyclics and Janssen Biotech, Inc. (a subsidiary of Johnson Johnson), was approved on November 13, 2013 by the US Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma (MCL), and thus became the first approved drug that directly targets Btk. On February 12, 2014, the FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy, and further expansion to patients with 17p deletion in CLL was approved on July 28, 2014. 

Kress, C.L., Konopleva, M., Martinez-Garcia, V., Krajewska, M., Lefebvre, S., Hyer, M.L., McQueen, T., Andreeff., M, Reed, J.C., and Ztqtata, J.M. (2(X)7). Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS ONE 2, e559. 

Tragara Pharmaceuticals, Inc. Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, http //www.clinicaltrials.gov/ct2/show/NCT01699152 [accessed Feh. 2014]. 

Chronic lympho- + cytic leukemia/ small cell lymphocytic lymphoma + + S S N N N N + S N N S... 

---